Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1Breast Diseases 1

Interventions

pembrolizumab 66Cyclophosphamide 44Cisplatin 43Nivolumab 36Paclitaxel 32Carboplatin 31Radiotherapy 29Gemcitabine 28Docetaxel 25Dexamethasone 22atezolizumab 21Doxorubicin 19Bevacizumab 19Magnetic Resonance Spectroscopy 17fludarabine 16Vincristine 16Lenalidomide 16Etoposide 16Radiosurgery 15Letrozole 15Ipilimumab 15Fluorouracil 15Blood Specimen Collection 15palbociclib 14Rituximab 14Radiation 14Leucovorin 14Cytarabine 14Surveys and Questionnaires 13Specimen Handling 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leflunomide × 90 days × Clear all
NCT03709446 2026-03-19

Leflunomide in Previously Treated Metastatic Triple Negative Cancers

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
17 enrolled
Breast

Breast Diseases, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡